The effect of tezepelumab on airway hyperresponsiveness to mannitol in asthma (UPSTREAM).

Competing Interests: Conflict of interest: A. Sverrild reports grants from The Capital Region of Denmark (public funding) and A.P. Moller Foundation (private funding), other (provision of study drugs) from AstraZeneca, during the conduct of the study; personal fees for advisory board and educational activities from AstraZeneca, Novartis and Chiesi, personal fees for advisory board work from Sanofi, outside the submitted work. Conflict of interest: S. Hansen has nothing to disclose. Conflict of interest: M. Hvidtfeldt has nothing to disclose. Conflict of interest: C-M. Clausson has nothing to disclose. Conflict of interest: O. Cozzolino has nothing to disclose. Conflict of interest: S. Cerps has nothing to disclose. Conflict of interest: L. Uller has nothing to disclose. Conflict of interest: V. Backer has nothing to disclose. Conflict of interest: J. Erjefält reports grants and personal fees from AstraZeneca and GlaxoSmithKline, outside of the submitted work, and is founder of Medetect AB, a CRO company collaborating with AstraZeneca, MedImmune, Regeneron, Sanofi Genzyme and Boehringer Ingelheim. Conflict of interest: C. Porsbjerg reports grants and personal fees for lectures, consultancy and advisory board work from AstraZeneca, Novartis, GlaxoSmithKline, Teva and Sanofi, grants and personal fees for lectures from Chiesi, outside the submitted work.